GlassScriptPhysician profile
Mubashar Munir
NPI 1518971944
$4,816.19
in general payments reported to CMS, 2019-2025
28 companies · $1,158 in 2025
The $1,158 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $360 · 2020: $234 · 2021: $445 · 2022: $758 · 2023: $988 · 2024: $874 · 2025: $1,158.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,019.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $822.70 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $807.50 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Abbvie INC. | $641.86 | 2019-2025 | |
| Janssen Biotech, INC. | $481.41 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Celgene Corporation | $298.94 | 2022-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $222.68 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $190.50 | 2019-2024 | Linzess |
| E.R. Squibb & Sons, L.L.C. | $134.50 | 2023 | Zeposia |
| Ardelyx, INC. | $119.71 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $108.38 | 2020-2024 | |
| Aimmune Therapeutics, INC. | $105.59 | 2024-2025 | Zenpep |
| Gilead Sciences, INC. | $104.64 | 2019-2021 | |
| Genzyme Corporation | $103.57 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $99.77 | 2019-2024 | Dificid |
| Lilly USA, LLC | $85.20 | 2024-2025 | Omvoh |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $71.59 | 2022-2023 | Dupixent |
| Qol Medical, LLC | $69.73 | 2024-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $65.58 | 2020-2022 | |
| Ipsen Biopharmaceuticals, INC | $58.53 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $51.67 | 2025 | Rezdiffra |
| Pfizer INC. | $34.44 | 2023-2025 | |
| Allergan, INC. | $31.81 | 2019-2020 | |
| Biocon Biologics INC | $21.01 | 2025 | Yesintek |
| Redhill Biopharma INC. | $19.97 | 2020 | |
| Braintree Laboratories, INC. | $17.74 | 2022 | |
| Organon LLC | $17.22 | 2023 | Hadlima, Renflexis |
| Daiichi Sankyo INC. | $15.04 | 2019 | |
| Janssen Scientific Affairs, LLC | $14.91 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mubashar Munir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.